AOP Orphan brings Thromboreductin to Russian market

4 November 2014

Austria-based rare diseases specialist AOP Orphan is expanding its sales area for Thromboreductin (anagrelide) to include the large Russian market.

This means that the drug, which represents an innovative treatment option for patients afflicted by essential thrombocythemia, is available in core Central European markets such as Austria, Hungary, Switzerland, Czech Republic and Poland as well as in Turkey, Israel, Kazakhstan and Russia, the company noted.

“We have started to offer our entire range of products, focusing on rare diseases, in Russia as well as the Middle East,” says Rudolf Widmann, chief executive of AOP Orphan, adding: “These regions are exciting markets. Above all, this way we can open up new treatment possibilities for patients in these countries."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK